Daily Archives: November 15, 2024
Meta-analysis: Urea May be Effective for the Treatment of SIADH-Induced Hyponatremia
15 Nov, 2024 | 14:01h | UTCBackground: Hyponatremia, defined as a serum sodium level below 135 mEq/L, is the most common electrolyte disorder in clinical practice, associated with increased mortality and prolonged hospital stays. The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a frequent cause of euvolemic hyponatremia, particularly among hospitalized patients. Traditional treatments like fluid restriction and hypertonic saline have limitations, and guidelines are inconsistent regarding their use. Urea, an osmotic diuretic, has been proposed as an alternative therapy but is underutilized due to concerns about efficacy, safety, and patient tolerability.
Objective: To evaluate the effectiveness and safety of urea in treating hyponatremia caused by SIADH.
Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines. Searches of MEDLINE, EMBASE, Cochrane CENTRAL, and Google Scholar up to November 2023 identified studies involving patients with SIADH-related hyponatremia treated with oral or nasogastric urea. Inclusion criteria encompassed clinical trials and observational studies reporting outcomes on serum sodium levels, symptom resolution, or adverse effects.
Results: Sixteen observational studies involving 518 patients (430 treated with urea) met inclusion criteria. Urea treatment significantly increased serum sodium levels (mean difference [MD], 9.21 mEq/L [95% CI, 7.36-11.06]; P < 0.01) despite high heterogeneity (I² = 89%). Subgroup analyses showed significant sodium increases at 24 hours and at 2, 3, 5, 7, 14 days, and 1 year post-treatment. Patients with severe hyponatremia (<120 mEq/L) experienced greater sodium increases (MD, 18.04 mEq/L [95% CI, 13.68-22.39]) compared to those with moderate (120-129 mEq/L) or mild (130-135 mEq/L) hyponatremia. Urea’s efficacy was comparable to fluid restriction (MD, 0.81 mEq/L [95% CI, –0.93 to 2.55]; P = 0.4) and vaptans (MD, –2.43 mEq/L [95% CI, –6.31 to 1.45]; P = 0.2), and superior to no treatment (MD, 7.99 mEq/L [95% CI, 6.25-9.72]; P < 0.01). Adverse events were minor; poor palatability was the most common complaint.
Conclusions: Urea is an effective and safe treatment for SIADH-induced hyponatremia, significantly increasing serum sodium levels, particularly in severe cases. It offers a viable alternative to fluid restriction and vaptans with minimal adverse effects.
Implications for Practice: Urea should be considered a valuable treatment option for SIADH-induced hyponatremia, especially in resource-limited settings or when other therapies are contraindicated or poorly tolerated. Its cost-effectiveness and ease of administration may improve patient outcomes and reduce healthcare costs.
Study Strengths and Limitations: Strengths include a comprehensive search strategy and inclusion of diverse studies across multiple settings. Limitations are the reliance on observational studies due to the absence of randomized controlled trials, significant heterogeneity among studies, and the potential for publication bias.
Future Research: Randomized controlled trials are necessary to confirm urea’s efficacy and safety, establish standardized dosing regimens, and develop strategies to enhance palatability and patient adherence.
Meta-Analysis: Spinal Cord Stimulation May Be Effective for Chronic Back and Leg Pain
15 Nov, 2024 | 13:43h | UTCBackground: Chronic back and leg pain causes significant disability worldwide. Spinal cord stimulation (SCS) offers treatment for patients unresponsive to conventional medical management (CMM). The comparative efficacy of conventional and novel SCS forms versus CMM is debated, requiring thorough evaluation.
Objective: To evaluate the efficacy of conventional and novel SCS therapies compared with CMM in adults with chronic back or leg pain who had not previously used SCS.
Methods: A systematic review and Bayesian network meta-analysis per PRISMA guidelines were performed. MEDLINE, Embase, and Cochrane Library were searched up to September 2, 2022. Thirteen RCTs with 1,561 patients were included. Interventions were conventional SCS, novel SCS modalities (e.g., high-frequency, burst stimulation), and CMM. Primary outcomes were pain intensity (visual analog scale) and responder rates (≥50% pain relief) in back or leg. Secondary outcomes were quality of life (EQ-5D index) and functional disability (Oswestry Disability Index).
Results: At 6 months, both conventional and novel SCS were superior to CMM in five of six outcomes. For back pain responder rates, conventional SCS had an OR of 3.00 (95% CrI, 1.49–6.72) and novel SCS had an OR of 8.76 (95% CrI, 3.84–22.31) versus CMM. Pain intensity in the back decreased significantly with conventional SCS (MD, –1.17; 95% CrI, –1.64 to –0.70) and novel SCS (MD, –2.34; 95% CrI, –2.96 to –1.73). Leg pain intensity also decreased significantly with conventional SCS (MD, –2.89; 95% CrI, –4.03 to –1.81) and novel SCS (MD, –4.01; 95% CrI, –5.31 to –2.75) compared to CMM. Quality of life improved with both SCS therapies (conventional SCS MD, 0.15; 95% CrI, 0.09–0.21; novel SCS MD, 0.17; 95% CrI, 0.13–0.21). Functional disability improved significantly with conventional SCS (MD, –7.10; 95% CrI, –10.91 to –3.36).
Conclusions: Both conventional and novel SCS therapies are associated with significant improvements in pain relief, quality of life, and functional ability compared with CMM in patients with chronic back and leg pain at 6 months.
Implications for Practice: The results support integrating SCS therapies into clinical practice for patients with chronic back and leg pain unresponsive to CMM.
Study Strengths and Limitations: Strengths include inclusion of recent RCTs and use of Bayesian network meta-analysis, allowing comprehensive evidence synthesis with both direct and indirect comparisons, enhancing reliability. Limitations involve potential biases due to challenges in blinding participants and assessors, as patients can perceive whether a device is active. Heterogeneity among studies in patient populations and interventions may affect generalizability. Inability to include long-term efficacy data due to crossover in many trials limits understanding of sustained outcomes.
Future Research: Long-term RCTs are needed to assess sustained efficacy and safety of SCS therapies. Future studies should compare different SCS modalities directly and identify patient subgroups most likely to benefit.
RCT: Tirzepatide Significantly Reduces Weight and Diabetes Risk in Obese Adults with Prediabetes
15 Nov, 2024 | 13:29h | UTCBackground: Obesity is a chronic disease that significantly increases the risk of type 2 diabetes, particularly in individuals with prediabetes. Weight reduction has been shown to improve insulin sensitivity and beta-cell function, potentially delaying or preventing the onset of type 2 diabetes. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated significant weight loss and glycemic control in short-term studies.
Objective: To evaluate the long-term efficacy and safety of tirzepatide in reducing body weight and delaying progression to type 2 diabetes in obese adults with prediabetes over a period of three years.
Methods: In this phase 3, double-blind, randomized, controlled trial (SURMOUNT-1), 1032 obese adults with prediabetes were randomized 1:1:1:1 to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo, alongside lifestyle intervention, for 176 weeks, followed by a 17-week off-treatment period. The primary endpoints included percent change in body weight and onset of type 2 diabetes during the treatment and follow-up periods.
Results: At week 176, participants receiving tirzepatide achieved significant mean weight reductions of –12.3% (5 mg), –18.7% (10 mg), and –19.7% (15 mg), compared to –1.3% with placebo (P<0.001 for all comparisons). Progression to type 2 diabetes was significantly lower in the tirzepatide groups (1.3%) compared to placebo (13.3%), with a hazard ratio of 0.07 (95% CI, 0.0 to 0.1; P<0.001). After the 17-week off-treatment period, 2.4% of tirzepatide-treated participants and 13.7% of placebo-treated participants had developed type 2 diabetes (hazard ratio, 0.12; 95% CI, 0.1 to 0.2; P<0.001). Common adverse events were gastrointestinal and generally mild to moderate.
Conclusions: Three years of tirzepatide treatment in obese adults with prediabetes resulted in substantial and sustained weight loss and significantly reduced the risk of progression to type 2 diabetes compared to placebo, with an acceptable safety profile.
Implications for Practice: Tirzepatide may be an effective long-term therapeutic option for weight management and diabetes prevention in obese patients with prediabetes, potentially altering clinical approaches to obesity and metabolic disease management.
Study Strengths and Limitations: Strengths include the long duration of the trial and large sample size, providing robust data on long-term efficacy and safety. Limitations involve participant attrition and higher withdrawal rates, especially in the placebo group, which may affect the generalizability of the findings.
Future Research: Further studies are needed to explore the mechanisms of tirzepatide’s effects on beta-cell function and insulin sensitivity, as well as its impact on cardiovascular outcomes and quality of life in diverse populations.